TSX:BHC (Bausch Health Companies Inc.)

About BHC

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.
  • Bausch Health Companies Inc. (TSX: BHC) Latest News

    The Motley Fool
    Energy Stocks

    Will These 3 Struggling Stocks Survive 2016?

    This year could be fatal for Penn West Petroleum Ltd. (TSX:PWT)(NYSE:PWE), Sears Canada Inc. (TSX:SCC), and Valeant Pharmaceuticals Intl Inc.…

    Read more »

    The Motley Fool
    Investing

    Good News for Valeant Pharmaceuticals Intl Inc.

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) gets some good news on its CEO search.

    Read more »

    The Motley Fool
    Investing

    Is Valeant Pharmaceuticals Intl Inc. Still an Option?

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has been through considerable controversy over the past few months, raising concerns about whether or…

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc. Is a Buy if its Parts Sell

    Until Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) sells some of its business and pays down debt, investors should still avoid it.…

    Read more »

    The Motley Fool
    Investing

    Should You Buy Valeant Pharmaceuticals Intl Inc.?

    Is Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) a falling knife you should avoid, or should you buy it with the potential…

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc.: This Hedge Fund Manager Says Buy

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is under fire, but hedge fund manager Bill Ackman says buy.

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc.: What Michael Pearson’s Testimony Means for the Company

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) shares declined by more than 7% after Michael Pearson was subpoenaed by a Senate committee.

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc.: What Exactly Is Going On Here?

    There was another suspicious press release from Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX).

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc.: Jim Chanos and the Original Short Thesis

    Jim Chanos was short Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) before the company ran into problems.

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc.: 2 Stories That Have Flown Under the Radar

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is fighting a multi-front war.

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc.: 3 Lessons From Bill Ackman’s Painful Experience

    Bill Ackman has made mistakes with Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) that the rest of us can learn from.

    Read more »

    The Motley Fool
    Investing

    Why Valeant Pharmaceuticals Intl Inc. Shares Surged as Much as 17% on Monday

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) shares soared after the company announced Michael Pearson will be stepping down.

    Read more »